Faron Pharmaceuticals Ltd: Holding(s) In Company

TURKU, FI / ACCESS Newswire / September 4, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS
1a. Identity of the issuer or the underlying issuer of existing shares:			Faron Pharmaceuticals Oy
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer					X
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of shares
An acquisition or disposal of financial instruments					X
An event changing the breakdown of shares outstanding
Other (please specify):
3. Details of person subject to the notification obligation
Name			Pentwater Capital Management LP
City and country of registered office (if applicable)			Naples, United States
4. Full name of shareholder(s) (if different from 3.)
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached:			01/09/2026
6. Date on which issuer notified (DD/MM/YYYY):			02/09/2026
7. Total positions of person(s) subject to the notification obligation
	% of shares outstanding (total of 8. A)	% of shares outstanding through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)		Total number of shares outstanding held in issuer
Resulting situation on the date on which threshold was crossed or reached		Less than 3%		Less than 3%
Position of previous notification (if applicable)		3.875746%		3.875746%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedv
A: Shares
Class/type of shares ISIN code (if possible)	Number of shares outstanding		% of shares outstanding
	Direct	Indirect	Direct	Indirect
SUBTOTAL 8. A

B 1: Financial Instruments as an entitlement to acquire
Type of financial instrument	Expiration date	Exercise/ Conversion Period	Number shares that may be acquired if the instrument is exercised/converted.	% of shares outstanding
		SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect
Type of financial instrument	Expiration date	Exercise/ Conversion Period	Physical or cash settlement	Number of shares	% of shares outstanding
Swap			Cash Settlement	Less than 3%	Less than 3%
			SUBTOTAL 8.B.2	Less than 3%	Less than 3%

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer
Full chain of controlled undertakings through which the shares and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity(please add additional rows as necessary)				X
Name	% of shares outstanding if it equals or is higher than the notifiable threshold	% of shares outstanding through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Matthew Halbower
MCH PWCM Holdings Inc.
Pentwater Capital Management LP		Less than 3%	Less than 3%
10. Additional information

Place of completion	Naples
Date of completion	02/09/2026

SOURCE: Faron Pharmaceuticals

View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/biotechnology/faron-pharmaceuticals-ltd-holdings-in-company-1216869